Octagon Capital Advisors LP Holds 1.785M Shares of Xilio Therapeutics

TL;DR

**Octagon Capital Advisors LP still holds 1.785M shares of Xilio Therapeutics.**

AI Summary

Octagon Capital Advisors LP, a Delaware-based investment firm, filed an amended Schedule 13G/A on February 5, 2024, disclosing its beneficial ownership in Xilio Therapeutics, Inc. As of December 31, 2023, Octagon Capital Advisors LP reported shared voting and dispositive power over 1,785,000 shares of Xilio Therapeutics' Common Stock. This filing indicates a significant institutional stake, which can influence investor confidence and potentially impact the stock's liquidity and trading patterns.

Why It Matters

This filing shows a major institutional investor, Octagon Capital Advisors LP, maintains a substantial stake in Xilio Therapeutics, which can signal confidence or influence future corporate actions.

Risk Assessment

Risk Level: low — This is an amendment to a passive ownership filing, indicating a stable or slightly adjusted institutional holding, which generally presents low risk.

Analyst Insight

Investors should note the continued institutional holding by Octagon Capital Advisors LP, which suggests a stable, long-term interest in Xilio Therapeutics, but this filing alone doesn't indicate a new catalyst.

Key Numbers

• 1,785,000 — Shares Beneficially Owned (Represents the total number of Xilio Therapeutics shares over which Octagon Capital Advisors LP has shared voting and dispositive power as of December 31, 2023.)

Key Players & Entities

• Octagon Capital Advisors LP (company) — the reporting person and beneficial owner
• Xilio Therapeutics, Inc. (company) — the subject company whose shares are being reported
• 1,785,000 (dollar_amount) — number of shares beneficially owned with shared voting and dispositive power
• Delaware (company) — place of organization for Octagon Capital Advisors LP
• December 31, 2023 (date) — date of the event requiring the filing

Forward-Looking Statements

• Octagon Capital Advisors LP will maintain a significant stake in Xilio Therapeutics for the foreseeable future. (Octagon Capital Advisors LP) — medium confidence, target: 12/31/2024

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securiti

Filing Documents

• o15240sc13ga1.htm (SC 13G/A) — 60KB
• 0001214659-24-001919.txt ( ) — 62KB

(a)

Item 1(a). Name of Issuer: XILIO THERAPEUTICS, INC.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 828 Winter Street Suite 300, Waltham, MA 02451

(a)

Item 2(a). Name of Person Filing: This statement is being jointly filed by: • Octagon Capital Advisors LP, a Delaware limited partnership, (“Octagon”) • Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands ("Master Fund") • Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”). Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships, each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: 645 Madison Avenue 21 st Floor, New York, NY 10065

(c)

Item 2(c). Citizenship: USA

(d)

Item 2(d). Title of Class of Securities: Common Stock, $0.0001 Par Value ("Common Shares" or "Shares")

(e)

Item 2(e). CUSIP Number: 98422T100 Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Act; (b) ¨ Bank as defined in Section 3(a)(6) of the Act; (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act; (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) ; (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F) ; (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) ; (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J) ; (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K) . If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 1,785,000; (b) Percent of Class: The percentage reported on this Schedule 13G, 6.48%, based on 27,542,000 shares of common stock outstanding as of November 7, 2023, as reported in the Form 10-Q filed by the issuer on November 9, 2023. 6.48% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: 1,785,000 (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispo

View Full Filing

View this SC 13G/A filing on SEC EDGAR